ImmunologyToday,voL 7, No. 7I, 1986
-holes Announcementfor subscribers, contributorsand advertisers
Owing to an expansion of activity by Elsevier Publications, Cambridge, the editorial, advertising and production offices of this journal must be refurbished during November and December.
Use of therapeutic plasma exchange endorsed An NIH consensus development panel recently considered the use of plasmapheresis in the treatment of a number of neurological illnesses and concluded that in the case of Guillain-Barr~ syndrome and myasthenia gravis use of the therapy resulted in clear-cut benefits. The panel hoped that the use of these procedures
Hybridoma Technology For those involved in hybridoma technology, Mansell Publishing have recently produced an authoritative guide to its complex literature over the past decade. Hybridoma Technology: an annotated listing of the key papers 1975-1985" is edited by Robin Nicholas, a Senior Scien-
Anti-cardiolipin test standardization There has been increasing clinical interest in antibodies that bind cardiolipin because of their apparent association with thrombosis and recurrent foetal loss. The Lupus Research Laboratory of the Rayne Institute in London recently sponsored an
332
Members of the journal's staff will be temporarily re-housed. Postal and telex communications will be unaffected but the number of the direct telephone line will be changed temporarily.
The numbers during this period only will be (0223) 358879, 358880 and 358882. Regrettably, calls received on (0223) 315961 will not be transferable but they will be answered and messages can be taken and calls returned.
During this period of disruption subscribers, contributers and advertisers may find it more difficult than usual to communicate with journal staff. There may also be delays in the production of the December and January issues, exacerbated by the holiday season at the end of December. We will do our best to minimize these problems but we apologize in advance to those affected and ask for their understanding.
would increase. However, a number of questions still need answers, including the optimum treatment regimen and the severity of illness required for the treatment to be effective. Its mechanism of action must be established and the NIH group felt that 'circumscribed' trials of the therapy might be useful in evaluating its efficacy in determining the pathogenic role of antibodies in diseases of 'unknown cause'. Eaton-Lambert syndrome, chronic inflammatory demyelinating polyneuro-
pathy and multiple sclerosis were among the other neurological illnesses considered by the panel. Definitive data are not yet available and the group were willing only to suggest a 'possible' role for plasma exchange in these diseases.
tific Officer at the UK Ministry of Agriculture's Central Veterinary Laboratory. It brings together particularly outstanding papers published in international Englishlanguage journals during the past 10 years in the whole area of hybridoma technology. The book contains over 500 abstracts and where appropriate the abstract briefly covers the background and context of the investigations reported in the paper and explains its major findings
and their implications. Appendices list books on hybridoma technology; the major journals in which the majority of the papers in the field appear; and the world's leading commercial producers of monoclonal antibodies.
international workshop to standardize ELISA and solid phase radioimmunoassay tests for these antibodies. The laboratory has now prepared 5 antisera for distribution to laboratories wishing to standardize the anti-cardiolipin test. In addition, a protocol has been established to evaluate the validity and reproducibility of the assay methods used by participating laboratories.
These reference sera and instructions for participation in the standardization process can be obtained by writing to Mrs Jill Harris, Lupus Research Laboratory, Rayne Institute, St Thomas's Hospital, London SE1 7EH, UK. There will be a charge of £50.00 to cover the cost of sample preparation, postage and computer analysis of each laboratory's results.
Copies of the consensus statement 'Utility of Therapeutic Plasmapheresisfor Neurological Disorders' can be obtained by writing to the office of Medical Applications of Research, NIH, Building 1 Room 216, Bethesda, MD 20892, USA.
*Published by Mansell Publishing Ltd., 6 All Saints Street, London N1 9RL, UK. Priced £25.00. ISBN 0 720 11798 4 (198 pages).
-holes Announcementfor subscribers, contributorsand advertisers
Owing to an expansion of activity by Elsevier Publications, Cambridge, the editorial, advertising and production offices of this journal must be refurbished during November and December.
Use of therapeutic plasma exchange endorsed An NIH consensus development panel recently considered the use of plasmapheresis in the treatment of a number of neurological illnesses and concluded that in the case of Guillain-Barr~ syndrome and myasthenia gravis use of the therapy resulted in clear-cut benefits. The panel hoped that the use of these procedures
Hybridoma Technology For those involved in hybridoma technology, Mansell Publishing have recently produced an authoritative guide to its complex literature over the past decade. Hybridoma Technology: an annotated listing of the key papers 1975-1985" is edited by Robin Nicholas, a Senior Scien-
Anti-cardiolipin test standardization There has been increasing clinical interest in antibodies that bind cardiolipin because of their apparent association with thrombosis and recurrent foetal loss. The Lupus Research Laboratory of the Rayne Institute in London recently sponsored an
332
Members of the journal's staff will be temporarily re-housed. Postal and telex communications will be unaffected but the number of the direct telephone line will be changed temporarily.
The numbers during this period only will be (0223) 358879, 358880 and 358882. Regrettably, calls received on (0223) 315961 will not be transferable but they will be answered and messages can be taken and calls returned.
During this period of disruption subscribers, contributers and advertisers may find it more difficult than usual to communicate with journal staff. There may also be delays in the production of the December and January issues, exacerbated by the holiday season at the end of December. We will do our best to minimize these problems but we apologize in advance to those affected and ask for their understanding.
would increase. However, a number of questions still need answers, including the optimum treatment regimen and the severity of illness required for the treatment to be effective. Its mechanism of action must be established and the NIH group felt that 'circumscribed' trials of the therapy might be useful in evaluating its efficacy in determining the pathogenic role of antibodies in diseases of 'unknown cause'. Eaton-Lambert syndrome, chronic inflammatory demyelinating polyneuro-
pathy and multiple sclerosis were among the other neurological illnesses considered by the panel. Definitive data are not yet available and the group were willing only to suggest a 'possible' role for plasma exchange in these diseases.
tific Officer at the UK Ministry of Agriculture's Central Veterinary Laboratory. It brings together particularly outstanding papers published in international Englishlanguage journals during the past 10 years in the whole area of hybridoma technology. The book contains over 500 abstracts and where appropriate the abstract briefly covers the background and context of the investigations reported in the paper and explains its major findings
and their implications. Appendices list books on hybridoma technology; the major journals in which the majority of the papers in the field appear; and the world's leading commercial producers of monoclonal antibodies.
international workshop to standardize ELISA and solid phase radioimmunoassay tests for these antibodies. The laboratory has now prepared 5 antisera for distribution to laboratories wishing to standardize the anti-cardiolipin test. In addition, a protocol has been established to evaluate the validity and reproducibility of the assay methods used by participating laboratories.
These reference sera and instructions for participation in the standardization process can be obtained by writing to Mrs Jill Harris, Lupus Research Laboratory, Rayne Institute, St Thomas's Hospital, London SE1 7EH, UK. There will be a charge of £50.00 to cover the cost of sample preparation, postage and computer analysis of each laboratory's results.
Copies of the consensus statement 'Utility of Therapeutic Plasmapheresisfor Neurological Disorders' can be obtained by writing to the office of Medical Applications of Research, NIH, Building 1 Room 216, Bethesda, MD 20892, USA.
*Published by Mansell Publishing Ltd., 6 All Saints Street, London N1 9RL, UK. Priced £25.00. ISBN 0 720 11798 4 (198 pages).
